# Phase 1, QT/QTC Interval Study in Healthy Subjects

> **NCT01910415** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 200 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Lumacaftor
- **DRUG:** Lumacaftor Placebo
- **DRUG:** Ivacaftor
- **DRUG:** Ivacaftor Placebo
- **DRUG:** moxifloxacin hydrochloride

## Key facts

- **NCT ID:** NCT01910415
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2014-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910415, "Phase 1, QT/QTC Interval Study in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01910415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*